Filing Flows › BioNexus Gene Lab (BGLC) › Q4 2024
BioNexus Gene Lab (BGLC) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 15, 2025
BioNexus Gene Lab (BGLC) reported revenue of $2.5M for the fourth quarter 2024 (Q4 2024), +11% from a year earlier and -4% from the quarter before. Operating margin was -16.5%, net earnings $348K (13.8% of revenue).
BioNexus Gene Lab, Q4 2024: revenue $2.5M (+11% year over year), operating margin -16.5%, net earnings $348K, operating cash flow −$70K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.5M | -4% | +11% |
| Operating profit | −$416K | — | — |
| Net earnings | $348K | — | — |
| Operating cash flow | −$70K | — | — |
What changed
Revenue was $2.5M in Q4 2024, up 11% year over year and down 4% from the previous quarter.
Gross margin was 12.3%, up 0.5 points from a year earlier. Operating costs exceeded revenue by $416K, an operating margin of -16.5%. Operating expenses grew 8143% against revenue growth of 11%. Net earnings were −$348K. The effective tax rate was -30.2%. Non-operating items added $684K, 256% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$70K. Non-cash charges added back $30K of depreciation. Working capital and other items used $448K. Capital expenditures of $4K exceeded it, leaving free cash flow of −$74K.
Questions
What was BioNexus Gene Lab's revenue in the fourth quarter 2024?
BioNexus Gene Lab (BGLC) reported revenue of $2.5M for the fourth quarter 2024 (Q4 2024), +11% from a year earlier and -4% from the quarter before.
Was BioNexus Gene Lab profitable in the fourth quarter 2024?
Operating loss was $416K (-16.5% of revenue) and net earnings $348K.
Source: BioNexus Gene Lab 10-K on SEC EDGAR.